Outlook Therapeutics, Inc.
OTLKCIK 0001649989 · Biological Products, (No Diagnostic Substances) · Nasdaq
- Oncobiologics, Inc. (until 2018-11-13)
Revenue (TTM)
$1.41M
Q2 May 2026
Net Income (TTM)
−$94.02M
+17.2% YoY
Q2 May 2026
EPS Diluted (TTM)
−$2.48
+55.9% YoY
Q2 May 2026
Gross Margin
4.0%
Q2 May 2026
Operating Margin
-3,937.0%
Q2 May 2026
Net Margin
-6,651.5%
Q2 May 2026
Free Cash Flow (TTM)
−$49.66M
Q2 May 2026
Cash
$7.75M
Q2 May 2026
Total Debt
$544.97M
Q2 May 2026
Shares Outstanding
120.86M sh
Q2 May 2026
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.